Shopping Cart
Remove All
Your shopping cart is currently empty
JNK3-IN-10
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T218271 Copy Product Info
🥰Excellent
JNK3-IN-10 is a JNK3 inhibitor that does not penetrate the blood-brain barrier and has an IC50 of 0.257 nM, exhibiting over 400-fold selectivity for JNK1. It blocks the JNK3-mediated signaling pathway downstream of TGF-β1, inhibits TGF-β1-induced phosphorylation of c-Jun, reduces the expression of pro-fibrotic markers, and restores epithelial protein E-cadherin (E-cadherin) expression. JNK3-IN-10 demonstrates low cytotoxicity and offers antifibrotic, cytoprotective, and renoprotective effects, alleviating albuminuria, glomerulosclerosis, and podocyte foot process fusion. It is applicable in research on chronic kidney disease, glomerulosclerosis, and adriamycin-induced nephropathy.
JNK3-IN-10
Cas No. 3085181-00-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | JNK3-IN-10 is a JNK3 inhibitor that does not penetrate the blood-brain barrier and has an IC50 of 0.257 nM, exhibiting over 400-fold selectivity for JNK1. It blocks the JNK3-mediated signaling pathway downstream of TGF-β1, inhibits TGF-β1-induced phosphorylation of c-Jun, reduces the expression of pro-fibrotic markers, and restores epithelial protein E-cadherin (E-cadherin) expression. JNK3-IN-10 demonstrates low cytotoxicity and offers antifibrotic, cytoprotective, and renoprotective effects, alleviating albuminuria, glomerulosclerosis, and podocyte foot process fusion. It is applicable in research on chronic kidney disease, glomerulosclerosis, and adriamycin-induced nephropathy. |
| Targets & IC50 | JNK3 (human):0.257 nM |
| In vitro | JNK3-IN-10 (Compound 14bg) exhibits a 84-fold, 472-fold, and 194-fold selectivity for JNK1, JNK2, and p38α, respectively, with minimal off-target kinase activity at a concentration of 1 μM, following pre-incubation for 20 minutes and co-incubation with ATP for 2 hours. At 1 μM concentration and 37 °C, JNK3-IN-10 shows moderate microsomal stability in human liver microsomes, retaining 64.63% after a 30-minute incubation. Its permeability through the blood-brain barrier (BBB) is low, with a P e value of 0.52×10^-6 cm/s, classifying it as a BBB non-permeable compound. Additionally, JNK3-IN-10 at 5 μM, pre-incubated for 1 hour, effectively inhibits TGF-β1-induced phosphorylation of c-Jun and the expression of profibrotic markers (PAI-1, COL1α1) in differentiated podocytes, without reducing cell viability. |
| In vivo | JNK3-IN-10 (Compound 14bg) (2-6 mg/kg; i.p.; three times a week; 2 weeks) significantly alleviates doxorubicin-induced nephropathy, albuminuria, glomerulosclerosis, and podocyte damage in male BALB/c mice, without exhibiting systemic toxicity. |
| Molecular Weight | 559.47 |
| Formula | C24H24Cl2N8O2S |
| Cas No. | 3085181-00-3 |
| Smiles | C(N)(=O)C1=CN2C(=C(N=C2S1)C3=CC(Cl)=C(Cl)C=C3)C4=NC(N[C@H]5CN(C(N(C)C)=O)CCC5)=NC=C4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: JNK3-IN-10 in vivo | JNK3-IN-10 in vitro | JNK3-IN-10 formula | JNK3-IN-10 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.